Women’s health programs throughout the world are largely focused on pre-emptively identifying and reducing the risk of cervical cancer. The focus is on screening women to identify who is at the highest risk for having a pre-cancerous lesion — the presence of tissue abnormalities that may progress to invasive cancer. The goal is to find and treat pre-cancerous lesions before they can progress.1,2
The techniques used in these efforts are well established in both the literature and clinical practice. Despite their effectiveness, they each have recognized shortcomings in analytical performance. Different tests typically are used in complementary or reflexive approaches that help clinicians feel more confident about their patient-care decisions.2
The need for improved sensitivity and specificity fuels an ongoing search for new testing technologies that balance analytical confidence with minimal intrusion for the patient.